Mesenbio
Newyork · Founded 2021
About Mesenbio
Mesenbio is a preclinical biopharmaceutical business based at the University of York. Its Cell Line Extracellular Vesicle Release (CLEVR) technique allows for a more diverse treatment pipeline by overcoming the most common hurdle in extracellular vesicle therapy.
Company Facts
- Founded: 2021
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $1.8M
- Funding stage: Seed
- Last round: Seed (Jan 2024)
- Website: https://www.mesenbio.net
Industries & Categories
Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/mesenbio-147821 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.